Literature DB >> 2492260

Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide.

G B Pier1, M Pollack.   

Abstract

A high-molecular-weight, immunogenic form of the lipopolysaccharide O side chain of Pseudomonas aeruginosa Fisher immunotype 4 (type 4, International Antigenic Typing System 1, Lanyi O:6) was isolated and characterized. Analysis by nuclear magnetic resonance spectroscopy confirmed the structural similarity of this high-molecular-weight polysaccharide and the type 4 O side chain. The polysaccharide was immunogenic in rabbits and mice, eliciting opsonophagocytic killing antibodies. Immunization with the polysaccharide produced significant protection against homologous challenge in both burned and granulocytopenic mice. Naturally acquired opsonic killing antibodies to type 4 polysaccharide were present in sera from unimmunized normal adults at levels comparable to postimmunization levels achieved after immunization with other type-specific polysaccharides. The specificity of the naturally occurring antibodies for the O side chain was documented by immunoblot analysis and inhibition studies. Naturally occurring polysaccharide-specific antibodies were comparable in their protective activity against live challenge in neutropenic animals to immunization-induced murine antibodies with similar specificity. These data suggest that naturally occurring serum antibody to P. aeruginosa type 4 lipopolysaccharide O side chains in most adults is not distinguishable in quantity or quality from immunization-induced antibodies in mice; evaluation of type 4-specific vaccines in humans may be complicated by this finding.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492260      PMCID: PMC313114          DOI: 10.1128/iai.57.2.426-431.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Stoichiometric depolymerization of polyuronides and glycosaminoglycuronans to monosaccharides following reduction of their carbodiimide-activated carboxyl groups.

Authors:  R L Taylor; H E Conrad
Journal:  Biochemistry       Date:  1972-04-11       Impact factor: 3.162

Review 2.  The structure of O-specific polysaccharides and serological classification of Pseudomonas aeruginosa (a review).

Authors:  E V Vinogradov; N A Kocharova; N A Paramonov; N K Kochetkov; B A Dmitriev; E S Stanislavsky; B Lányi
Journal:  Acta Microbiol Hung       Date:  1988

3.  Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa.

Authors:  G B Pier; H F Sidberry; S Zolyomi; J C Sadoff
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

4.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

5.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors:  G B Pier
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

6.  Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa.

Authors:  G B Pier; D M Thomas
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

7.  High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.

Authors:  G B Pier; H F Sidberry; J C Sadoff
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

8.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

9.  Antibody response to capsular polysaccharides of groups A and C neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease.

Authors:  H Käyhty; H Jousimies-Somer; H Peltola; P H Mäketä
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

10.  Somatic Antigens of Pseudomonas aeruginosa. The structure of the polysaccharide chain of Ps.aeruginosa O:6 (Lanyi) lipopolysaccharide.

Authors:  B A Dmitriev; N A Kocharova; Y A Knirel; A S Shashkov; N K Kochetkov; E S Stanislavsky; G M Mashilova
Journal:  Eur J Biochem       Date:  1982-06-15
View more
  11 in total

1.  A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.

Authors:  Tanweer S Zaidi; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

2.  Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.

Authors:  Gregory P Priebe; Mary M Brinig; Kazue Hatano; Martha Grout; Fadie T Coleman; Gerald B Pier; Joanna B Goldberg
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

3.  Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.

Authors:  Antonio DiGiandomenico; Jayasimha Rao; Joanna B Goldberg
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

4.  Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.

Authors:  Gregory P Priebe; Gloria J Meluleni; Fadie T Coleman; Joanna B Goldberg; Gerald B Pier
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

5.  Pseudomonas aeruginosa lipopolysaccharide: evidence that the O side chains and common antigens are on the same molecule.

Authors:  K Hatano; J B Goldberg; G B Pier
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

6.  Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.

Authors:  G B Pier; S Takeda; M Grout; R B Markham
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

7.  Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.

Authors:  J F Pittet; M A Matthay; G Pier; M Grady; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

8.  Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Authors:  G B Pier; N L Koles; G Meluleni; K Hatano; M Pollack
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

9.  Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.

Authors:  K Hatano; G B Pier
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

10.  Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Authors:  K Hatano; S Boisot; D DesJardins; D C Wright; J Brisker; G B Pier
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.